Multidisciplinary Association For Psychedelic Studies, Inc.

In 2023, Biden Administration recommended cannabis reclassification, with progress continuing into 2024. The FDA rejected MDMA-assisted therapy for PTSD in August, with another clinical trial planned. Boulder's Cannabis Licensing and Advisory Board considered a marijuana concentrates ban, which the industry opposes. Colorado prepared for psychedelic healing centers, with training programs approved and licenses available from December. Naropa's psychedelic program was delayed but will be run by Memoru Center. Healing centers will initially use psilocybin and psilocin, with potential expansion to other substances in 2026.

FDA approves a clinical trial involving 320 veterans with PTSD, including Michiganders, to study marijuana's effects. MAPS, conducting the trial, received a $12.9 million grant from Michigan. The study will involve smoking marijuana with higher THC concentrations, aiming to provide more scientific data on its potential benefits for PTSD symptoms.

Robert F. Kennedy Jr. and other prominent Republicans have recently endorsed psychedelics, despite their historical association with the far-right libertarian crowd. This shift is seen as a potential revival for the psychedelic movement, which has shown signs of losing steam. However, concerns arise over the potential for right-wing leadership to fast-track psychedelics without ensuring adequate mental health and societal supports. Despite setbacks, such as the FDA's rejection of MDMA therapy for PTSD, momentum for psychedelic legalization continues, with states like Oregon and Colorado leading the way. The integration of psychedelics into mainstream politics reflects their growing acceptance across party lines, though the industry's future remains uncertain.

FDA approves cannabis study on 320 veterans with PTSD, potentially impacting the cannabis sector. MAPS leads the $13 million trial, focusing on high-THC cannabis's therapeutic value. Results could take years to affect the market.

FDA approves clinical trial investigating if smoking/vaping medical cannabis can treat PTSD in veterans, funded by Michigan Veteran Marijuana Research Grant Program and sponsored by MAPS. Trial faced delays in 2021 due to FDA concerns about inhalation risks and self-titration dosing, but objections were resolved. The study will involve 320 veterans with moderate to severe PTSD, using high-potency cannabis products from Canada.

FDA approves cannabis study on 320 veterans with PTSD, potentially impacting the cannabis sector. MAPS leads the $13 million trial, focusing on high-THC cannabis's therapeutic value.

After years of delays, FDA approves Phase 2 of MAPS' study on smoked medical marijuana for PTSD in veterans, funded by Michigan's cannabis tax revenue.

The FDA approved a clinical trial, MJP2, to study medical marijuana's efficacy for PTSD in veterans, after MAPS' persistent lobbying. The study, funded by Michigan, aims to bridge the gap in high-quality data on cannabis's safety and effectiveness.

FDA clears phase 2 study to test smoked cannabis in 320 veterans with PTSD, funded by Michigan Veteran Marijuana Research Grant Program. MAPS resolved FDA concerns, allowing self-titration of high THC potency cannabis. MJP2 study aims to compare inhaled high THC-potency cannabis with placebo, excluding patients with respiratory conditions.

Cybin Inc. and MindMed Inc. plan to start phase 3 trials for psilocybin and LSD treatments in 2023, aiming for 2026 results. Despite recent setbacks, including FDA rejections and data issues, both companies remain optimistic, supported by FDA approvals and cautious analyst optimism.